The envelope glycoprotein of human immunodeficiency virus type 2 (HIV-2) is primarily responsible for virus attachment and entry into the target cell population. We constructed an HIV-2 mutant virus containing an in-frame deletion within the putative CD4-binding sequences of the envelope glycoprotein and confirmed that the mutant envelope is unable to bind CD4 and that the mutant virus is noninfectious. To investigate whether this mutant could dominantly interfere with wild-type replication, we coexpressed proviral DNAs of both wild-type and mutant viruses in cells and assayed the production of infectious HIV-2 virions. Interference with virus replication was indeed observed with mutant DNA, and a maximal effect was achieved with 10-fold excess mutant DNA over wild-type DNA in the cotransfection experiments. The transdominant effect on virus replication does not appear to be at the level of wild-type envelope expression or gpl20-CD4 interaction. Rather, the interference may be at the level of mixed-oligomer formation during progeny virus assembly and may occur by either destabilizing the multimeric structure of gpl20 or forming a defective mixed multimeric gpl20 which is unable to complete the receptor binding and/or postbinding events needed for infection.
The generation of a dominant negative phenotype provides a novel approach for inhibiting the normal function of a gene (8) . Dominant negative mutations directed at essential genes during virus replication have been examined for use in possible antiviral strategies against human immunodeficiency virus (HIV) infection. The two major regulatory proteins of HIV-1, Tat and Rev, have recently been targeted for such an approach (26) . A mutational analysis of Tat has generated several transdominant mutants which can effectively inhibit wild-type Tat function on the HIV promoter in vitro (17, 21) . A dominant negative phenotype of Rev has also been shown to repress wild-type Rev function when supplied in trans (15) . In addition, mutations in the core structural protein Gag and the amino-terminal domain of the transmembrane glycoprotein gp4l of HIV-1 have generated mutants which can dominantly interfere with wild-type virus replication in vitro (6, 27) . For the gp4l dominant negative mutant, a dramatic interfering effect on syncytium formation and infectivity of HIV-1 was seen, even in the presence of excess wild-type gp4l. A study conducted in our laboratory characterized viruses containing mutations in a similar fusogenic sequence in the amino-terminal domain of gp4l of HIV-2 (25) . Although these HIV-2 mutant viruses, which are severely impaired in their fusogenic function, did not dominantly interfere with virus infection, they did diminish the capacity of the wild-type virus to induce syncytia, suggesting that an interfering effect on syncytium formation was exerted by the mutant gp4l glycoprotein (24) . These results indicate that the env gene may be an appropriate target for generation of transdominant mutants.
The envelope glycoprotein of HIV is initially synthesized as a precursor (gpl60) which is proteolytically cleaved into the envelope glycoprotein gpl20 and the transmembrane glycoprotein gp4l. Previous reports have shown that the * Corresponding author. t Present address: Abbott Laboratories, Abbott Park, IL 60064. envelope glycoprotein gpl20 of HIV-1 and HIV-2 most probably organizes into multimeric structures before virion assembly (1, 3, 22, 30) . Therefore, an envelope mutant may be able to interfere with the production of infectious wildtype virus by disrupting multimerization of gpl20 or inactivating the polypeptide complex.
We have initiated a study to determine whether an HIV-2 mutant containing a deletion within the putative CD4-binding domain of the envelope glycoprotein could inhibit wildtype virus production. This mutant virus is completely noninfectious, and the mutant envelope protein is unable to bind to soluble CD4. The generation of wild-type virus was dominantly interfered with in the presence of increasing proportions of mutant to wild-type proviral DNA in cotransfected cells. The dominant phenotype is not accounted for by impairment of wild-type envelope expression or wild-type gpl20-CD4 interaction. We propose that this interference most probably resides at the level of envelope multimerization and/or virion stability.
MATERUILS AND METHODS
Cell lines and DNA. CV-1, COS-1, and HeLa cells were maintained in Dulbecco's minimal essential medium with 10% fetal calf serum. Human TK-143B cells were maintained in Dulbecco's minimal essential medium containing 10% fetal calf serum and 20 mg of 5-bromodeoxyuridine per ml. H9 cells were maintained in RPMI 1640 medium with 10% fetal calf serum. The complete HIV-2Sbil/iSy provirus (5) was obtained as two subclones, pEGP and pKF-3, which yield infectious virus following ligation at a common Sacl restriction site and transfection into host cells (7) .
Mutagenesis and plasmid constructions. The deletion mutation of the env gene was performed with pKF-3. A 1,230-bp EcoRI-BamHI fragment containing the putative gpl20 CD4-binding site was subcloned into M13mpl9. Oligonucleotide site-directed mutagenesis was performed es-sentially as described by Kunkel et al. (10) (Fig. 1 ). This mutation (ACD4env) eliminates four amino acids in the HIV-2 env gpl20 corresponding to residues critical for the interaction between HIV-1 env gpl20 and the CD4 protein (12, 19 Fig. 2A) . Although the mutant envelope may have undergone some conformational changes as a result of the deletion, it has remained immunogenic as evidenced by the radioimmunoprecipitation analysis.
The detection of the surface glycoprotein gpl20 in the cell medium indicates proteolytic cleavage of the precursor envelope glycoprotein, gpl60, into the products gpl20 and gp4l and the subsequent transport of the mature envelope glycoproteins to the cell surface (9) . To investigate the processing and transport of the present mutant envelope glycoprotein, we assayed for extracellular HIV-2 gpl20 in the cell medium. The medium of 35S-labeled CV-1 cells infected with the HIV-2 recombinant vaccinia viruses was immunoprecipitated with HIV-2 patient sera and subjected to SDS-polyacrylamide gel electrophoresis analysis. gpl20 was evident in the medium of the infected cells, indicating that the deletion within the CD4-binding domain did not affect processing and transport of the mature gpl20 glycoprotein (Fig. 2B) .
To demonstrate that the ability of the mutant envelope glycoprotein to bind CD4 has been eliminated by the deletion mutation, we performed radioimmunoprecipitations on VVen-and VVACD4env-infected COS-1 cell lysates by using sCD4 coupled to OKT4-protein A-Sepharose. No binding between the ACD4env protein and sCD4 was observed when compared with the wild-type envelope protein (see Fig. 4,  lanes 2 and 3) . Therefore, the same region of gpl20 previously shown to be important for HIV-1 gpl2O-CD4 interaction also appears to be critical for HIV-2 gpl20.
Phenotypic analysis of the HIV envelope mutant genome. A phenotypic analysis of the HIV-2 ACD4env mutant was tested by transfecting COS-1 cells with proviral DNA of the mutant in parallel with wild-type DNA and measuring for p26 antigen production. Whereas the p26 activity in COS-1 cell lysates were nearly equivalent for both viruses, cells transfected with ACD4env DNA unexpectedly but consistently produced 5-to 10-fold lower p26 activity in the supernatant than the wild-type DNA did (Table 1) . To assess the relative infectivity of the ACD4env mutant virus, H9 cells were exposed to wild-type and mutant DNA-transfected cell supernatants adjusted for equivalent amounts of antigen and assayed for p26 activity over a 3-week period. (Fig. 4) .
Expression of Gag protein in the presence of mutant and wild-type envelope glycoproteins. The finding of a decrease in the level of extracellular Gag protein released from cells transfected by the envelope mutant virus was unexpected.
Recently it has been shown that a direct interaction between envelope and Gag protein may exist during virus assembly and that this interaction may influence the site of virus release from the infected cell (20 (3, 22, 30) . Specifically, the data of Chakrabarti et al. (1) (28) , provided that such a deletion would not destabilize the protein or significantly alter its immunogenicity. The study reported here suggests that the HIV-2 gp120 deleted in sequences within the putative CD4-binding site is stable, is processed and recognized by antibodies directed against the wild-type envelope protein, but is unable to bind CD4. Furthermore, such an env mutant is also capable of interfering with the replication of wild-type virus. Although high levels of the interfering protein are necessary to inhibit virus replication, a lower level may be sufficient to induce immunity. Thus, a mutant envelope gene which is expressed at a basal level but superinducible upon HIV infection may function dually as a vaccine and an antiviral compound. Refinement of such approaches may add to the arsenal of strategies against HIV.
